Literature DB >> 23308370

Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.

Victor Musiime1, Elizabeth Kaudha, Joshua Kayiwa, Grace Mirembe, Matthew Odera, Hilda Kizito, Immaculate Nankya, Francis Ssali, Cissy Kityo, Robert Colebunders, Peter Mugyenyi.   

Abstract

We sought to determine the pattern of resistance-associated mutations (RAMs) among HIV-1-infected children failing first-line antiretroviral therapy (ART) and ascertain their response to second-line regimens in 48 weeks of follow-up. The design involved a cohort study within an HIV care program. We studied records of 142 children on ART with virological failure to first-line ART and switched to second-line ART with prior genotypic resistance testing. The pattern of RAMs was determined in frequency runs and the factors associated with accumulation of≥3 thymidine analogue mutations (TAMs) and K103N were determined using multivariate logistic models. Changes in weight, height, CD4, and viral load at weeks 24 and 48 after switch to second-line therapy were determined using descriptive statistics. The children were mean age 10.9±4.6 years and 55.6% were male. The commonest nucleoside reverse transcriptase inhibitor (NRTI) RAM was M184V in 129/142 (90.8%) children. TAMs,≥3 TAMs, 69 insertion complex, K65R/N, and Q151M were observed in 43.0%, 10.6%, 18.3%, 2.8%, and 2.1% of the children, respectively. The commonest nonnucleoside reverse transcriptase inhibitor (NNRTI) RAM was K103N in 72/142 (50.7%) children. The starting ART regimen was associated with accumulation of both≥3 TAMs (p=0.046) and K103N (p<0.0001), while a history of poor adherence was associated with K103N accumulation (p=0.0388). After 24 weeks and 48 weeks of follow-up on lopinavir-ritonavir based second-line ART, 86/108 (79.6%) and 84.5% (87/103) of the children had viral loads<400 copies/ml, respectively. The mean CD4 absolute count increased by 173 cells/μl and 267cells/μl at weeks 24 and 48, respectively. Increments were also observed in mean weight (1.6 kg and 4.3 kg) and height (1.8 cm and 5.8 cm) at weeks 24 and 48, respectively. Multiple RAMs were observed among HIV-1-infected children with virological failure on first-line ART with M184V and K103N most frequent. The children responded favorably to boosted PI-based second-line ART.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23308370     DOI: 10.1089/aid.2012.0283

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

1.  Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.

Authors:  Wasana Prasitsuebsai; Sirinya Teeraananchai; Thida Singtoroj; Khanh Huu Truong; Jintanat Ananworanich; Viet Chau Do; Lam Van Nguyen; Pope Kosalaraksa; Nia Kurniati; Tavitiya Sudjaritruk; Kulkanya Chokephaibulkit; Stephen J Kerr; Annette H Sohn
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

2.  Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.

Authors:  George K Siberry; Anouk Amzel; Artur Ramos; Emilia D Rivadeneira
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

3.  Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.

Authors:  Tristan Childs; Delane Shingadia; Ruth Goodall; Katja Doerholt; Hermione Lyall; Trinh Duong; Ali Judd; Di M Gibb; Intira Jeannie Collins
Journal:  Lancet HIV       Date:  2015-04       Impact factor: 12.767

4.  Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up.

Authors:  Dorothy E Dow; Aisa M Shayo; Coleen K Cunningham; Elizabeth A Reddy
Journal:  BMC Infect Dis       Date:  2014-11-07       Impact factor: 3.090

5.  Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.

Authors:  Philippe R Mutwa; Kimberly R Boer; Brenda Asiimwe-Kateera; Diane Tuyishimire; Narcisse Muganga; Joep M A Lange; Janneke van de Wijgert; Anita Asiimwe; Peter Reiss; Sibyl P M Geelen
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

6.  Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.

Authors: 
Journal:  Clin Infect Dis       Date:  2018-02-01       Impact factor: 9.079

7.  The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study.

Authors:  Janne Estill; Nathan Ford; Luisa Salazar-Vizcaya; Andreas D Haas; Nello Blaser; Vincent Habiyambere; Olivia Keiser
Journal:  Lancet HIV       Date:  2016-02-16       Impact factor: 12.767

Review 8.  Development of antiretroviral resistance in children with HIV in low- and middle-income countries.

Authors:  Felicity Fitzgerald; Martina Penazzato; Diana Gibb
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

9.  Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.

Authors: 
Journal:  Lancet       Date:  2013-03-07       Impact factor: 79.321

10.  Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.

Authors:  Lisa L Ross; Mark F Cotton; Haseena Cassim; Eugeny Voronin; Naomi Givens; Jorg Sievers; Katharine Y Cheng
Journal:  Open AIDS J       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.